“…HD affects the whole brain, but the most prominent early effect is characterized by a loss of small to medium spiny neurons in the caudate and putamen (Vonsattel & DiFiglia, 1998). However, other neuropathology (e.g., corticostriatal gray-matter atrophy, white-matter volume loss) and subtle signs of the disease, including cognitive changes, are seen during the prodromal HD (prHD) phase, decades prior to the diagnosis of manifest HD (Duff et al, 2010; Harrington, Smith, Zhang, Carlozzi, & Paulsen, 2012; Nopoulos et al, 2010; Novak et al, 2012; Paulsen et al, 2006; Paulsen et al, 2008; Paulsen et al, 2001; Rosas et al, 2005). In conjunction with efforts to identify efficacious treatments to slow disease progression, there has been a concerted effort to identify neuroimaging biomarkers of early brain changes that could serve as outcomes in primary prevention trials of individuals in the prHD phase, when treatments are more likely to succeed.…”